Sector News

FDA grants GSK first-ever approval for RSV vaccine

May 6, 2023
Life sciences

After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).

The approval comes after an FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted in support of Arexvy’s effectiveness and safety. Furthermore, in April 2023, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion in support of the vaccine’s approval. These recommendations and the FDA approval were based on positive AReSVi-006 Phase III trial data. Results from the trial showed a statistically significant and clinically meaningful overall efficacy of 82.6% against RSV-LRTD in adults ages 60 years and over. Additionally, efficacy in reducing the risk of severe RSV-associated lower LRTD was 94.6% in older adults with at least one underlying medical condition of interest like certain cardiorespiratory and endocrine-metabolic conditions. The study will continue for three RSV seasons to test the duration of effectiveness and the safety and effectiveness of repeat vaccination.

Arexvy contains a combination of a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) and GSK’s proprietary AS01E adjuvant. GSK’s vaccine is one of a cohort of RSV vaccines that has reached later stages of development this year. Pfizer’s RSV vaccine will soon also face a US regulatory decision with an upcoming Prescription Drug User Fee Act (PDUFA) date later in May. Moderna and Bavarian Nordic are also running Phase III trials with their RSV vaccine candidates.

In June, the Advisory Committee on Immunization Practices (ACIP) will give guidelines on the appropriate use of the vaccine in the US. In a press release, GSK also announced that the vaccine will be available for older adults before the 2023/24 RSV season. RSV season usually begins in autumn and peaks in the winter months in the Northern hemisphere.

In a May 3 press release, the director of the FDA’s Center for Biologics Evaluation and Research Dr. Peter Marks said, “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States”.

By Akosua Mireku

Source: pharmaceutical-technology.com

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach